Search results
SYS c020033 LBL ^^^^^nam^^22^^^^^^^^450^ 005 20011211161711.0 010 $a 0-444-81015-3 100 $a 19980129d1988 u y0sloc0103 ba 101 0-
$a eng 102 $a NL 105 $a y z 000yy 200 1-
$a Cancer chemotherapy and biological response modifiers annual $h 10 $f edit. H. M. Pinedo, D. L. Longo, B. A. Chabner 210 $a Amsterdam $c Elsevier $d 1988 215 $a xix, 594 s. 606 $a nádory $x farmakoterapia $2 mesh $3 sllk_un_auth*d009369 606 $a metastázy nádorové $x farmakoterapia $2 mesh $3 sllk_un_auth*d009362 606 $a imunogenetika $2 mesh $3 sllk_un_auth*d007125 606 $a interferóny $x použitie terapeutické $2 mesh $3 sllk_un_auth*d007372 606 $a interleukíny $2 mesh $3 sllk_un_auth*d007378 606 $a cytokíny $2 mesh $3 sllk_un_auth*d016207 606 $3 sllk_un_auth*d000970 $a antineoplastiká $x použitie terapeutické $2 mesh 675 $a 616-006-033-085.277.3:578.245.2 $v 1. stred. $z slo 702 -1
$3 sllk_un_auth*p0002717 $a Pinedo $b H. M. $g Herbert M. $4 340 702 -1
$a Longo $b Dan L. $3 sllk_un_auth*p0003748 $4 340 $p National Institute on Aging, National Institutes of Health, Gerontology Research Center, Bethesda and Baltimore, USA 702 -1
$3 sllk_un_auth*p0002718 $a Chabner $b B. A. $g Bruce A. $4 340 801 -0
$a SK $b BA006 $c 19981223 $g AACR2 SYS c051875 LBL ^^^^^nam^^22^^^^^^^^450^ 005 20011211162814.0 010 $a 0-444-90485-9 100 $a 19990819d1987 m y0sloc0103 ba 101 0-
$a eng 102 $a NL 105 $a y z 000yy 200 1-
$a Cancer chemotherapy and biological response modifiers annual $h 9 $f edit. H. M. Pinedo, D. L. Longo, B. A. Chabner 210 $a Amsterdam $c Elsevier $d 1987 215 $a xvi, 572 s. 606 $a karcinóm $x farmakoterapia $2 mesh $3 sllk_un_auth*d002277 675 $a 616-006.6-092:615.277.3 $v 1. stred. $z slo 702 -1
$3 sllk_un_auth*p0002717 $a Pinedo $b H. M. $g Herbert M. $4 340 702 -1
$a Longo $b Dan L. $3 sllk_un_auth*p0003748 $4 340 $p National Institute on Aging, National Institutes of Health, Gerontology Research Center, Bethesda and Baltimore, USA 702 -1
$3 sllk_un_auth*p0002718 $a Chabner $b B. A. $g Bruce A. $4 340 801 -0
$a SK $b BA006 $c 19990819 $g AACR2 SYS c051368 LBL ^^^^^nam^^22^^^^^^^^450^ 005 20000515145252.0 100 $a 19990625d1984 m y0sloc0103 ba 101 0-
$a eng 102 $a NL 105 $a y z 000yy 200 1-
$a Cancer chemotherapy $e <the> EORTC cancer chemotherapy annual $h 6. $f edit. H. M. Pinedo, B. A. Chabner 210 $a Amsterdam $c Elsevier $d 1984 215 $a 14, 550 s. 606 $a nádory $x farmakoterapia $x ročenky $2 mesh $3 sllk_un_auth*d009369 675 $a 616-006.6:615.277.3 $v 1. stred. $z slo 702 -1
$3 sllk_un_auth*p0002717 $a Pinedo $b H. M. $g Herbert M. $4 340 702 -1
$3 sllk_un_auth*p0002718 $a Chabner $b B. A. $g Bruce A. $4 340 801 -0
$a SK $b BA006 $c 19990625 $g AACR2 SYS c021044 LBL ^^^^^nam^^22^^^^^^^^450^ 005 20010123110854.0 010 $a 0-444-90395-X 100 $a 19980512d1985 u y0sloc0103 ba 101 0-
$a eng 102 $a NL 105 $a a z 000yy 200 1-
$a Cancer chemotherapy $e <the> EORTC cancer chemotherapy annual $h 7. $f Edit. H. M. Pinedo, B. A. Chabner 210 $a Amsterdam $c Elsevier $d 1985 215 $a 17, 520 s. $c il. 225 2-
$a Annual $v 7 $x 0167-7853 410 -1
$1 001 sllk_un_auth*e000737 $1 500 10 $a Annual 541 1-
$a Chemoterapia nádorov 606 $a antimetabolity protinádorové $x farmakokinetika $2 mesh $3 sllk_un_auth*d000964 606 $a farmakoterapia $2 mesh $3 sllk_un_auth*d004358 606 $a zlúčeniny nitrózomočoviny $2 mesh $3 sllk_un_auth*d009607 606 $a triazény $2 mesh $3 sllk_un_auth*d014226 606 $a zlúčeniny organoplatinové $2 mesh $3 sllk_un_auth*d009944 606 $a cisplatina $x farmakokinetika $2 mesh $3 sllk_un_auth*d002945 606 $a antikarcinogény $2 mesh $3 sllk_un_auth*d016588 606 $a imunoterapia $2 mesh $3 sllk_un_auth*d007167 606 $a nádory $x farmakoterapia $2 mesh $3 sllk_un_auth*d009369 606 $a lymfóm $2 mesh $3 sllk_un_auth*d008223 606 $a Hodgkinova choroba $2 mesh $3 sllk_un_auth*d006689 606 $3 sllk_un_auth*d018906 $a antineoplastiká alkylačné $2 mesh 606 $a antracyklíny $2 mesh $3 sllk_un_auth*d018943 675 $a 616-006-085.277.3:615.277:615.37 $v 1. stred. $z slo 702 -1
$3 sllk_un_auth*p0002717 $a Pinedo $b H. M. $g Herbert M. $4 340 702 -1
$3 sllk_un_auth*p0002718 $a Chabner $b B. A. $g Bruce A. $4 340 801 -0
$a SK $b BA006 $c 19981223 $g AACR2 SYS c052431 LBL ^^^^^nam^^22^^^^^^^^450^ 005 20000515145557.0 010 $a 0-444-90426-3 100 $a 19990908d1986 m y0sloc0103 ba 101 0-
$a eng 102 $a NL 105 $a y z 000yy 200 1-
$a Cancer chemotherapy $e <the> eorts cancer chemotherapy annual $h 8 $f editors H. M. Pinedo, B. A. Chabner 210 $a Amsterdam $c Elsevier $d 1986 215 $a 15, 588 s. 606 $a karcinóm $2 mesh $3 sllk_un_auth*d002277 606 $a farmakoterapia $2 mesh $3 sllk_un_auth*d004358 675 $a 616-006.6:615.277 $v 1. stred. $z slo 702 -1
$3 sllk_un_auth*p0002717 $a Pinedo $b H. M. $g Herbert M. $4 340 702 -1
$3 sllk_un_auth*p0002718 $a Chabner $b B. A. $g Bruce A. $4 340 801 -0
$a SK $b BA006 $c 19990908 $g AACR2 SYS c013952 LBL ^^^^^nam^^22^^^^^^^^450^ 005 20060908125053.0 010 $a 0-19-262663-9 100 $a 19951201d1995 m y0sloc0103 ba 101 0-
$a eng 102 $a GB 105 $a a z 000yy 200 1-
$a Oxford textbook of oncology $h Vol. 1 $f edit. Michael Peckham, Herbert M. Pinedo, Umberto Veronesi 210 $a Oxford, U.K. $c Oxford University Press $d 1995 215 $a xxiii, 1240, 124 s. $c il. 541 1-
$a Oxfordská učebnica onkológie $h Zv. 1 $z slo 606 $a onkológia lekárska $2 mesh $3 sllk_un_auth*d008495 606 $a nádory $x etiológia $x epidemiológia $x prevencia a kontrola $2 mesh $3 sllk_un_auth*d009369 606 $a nádory $x diagnostika rádioizotopová $2 mesh $3 sllk_un_auth*d009369 606 $a nádory $x farmakoterapia $2 mesh $3 sllk_un_auth*d009369 606 $a nádory hlavy a krku $2 mesh $3 sllk_un_auth*d006258 606 $a nádory kože $2 mesh $3 sllk_un_auth*d012878 606 $a nádory gastrointestinálne $2 mesh $3 sllk_un_auth*d005770 606 $a tomografia emisná počítačová $2 mesh $3 sllk_un_auth*d014055 606 $a MRI $2 mesh $3 sllk_un_auth*d008279 606 $a ultrasonografia $2 mesh $3 sllk_un_auth*d014463 606 $3 sllk_un_auth*d014408 $a biomarkery nádorové $x použitie diagnostické $2 mesh 606 $a MR spektroskopia $2 mesh $3 sllk_un_auth*d009682 606 $a cisplatina $x použitie terapeutické $2 mesh $3 sllk_un_auth*d002945 606 $a hormóny $x použitie terapeutické $2 mesh $3 sllk_un_auth*d006728 606 $a rádioterapia $x metódy $2 mesh $3 sllk_un_auth*d011878 606 $a hypertermia indukovaná $2 mesh $3 sllk_un_auth*d006979 606 $a lasery $2 mesh $3 sllk_un_auth*d007834 606 $a nádory $x klasifikácia $2 mesh $3 sllk_un_auth*d009369 675 $a 616-006.6-073.432.19-085 $v 1. stred. $z slo 702 -1
$a Peckham $b Michael J. $3 sllk_un_auth*p0003400 $4 340 702 -1
$a Pinedo $b H. M. $g Herbert M. $3 sllk_un_auth*p0002717 $4 340 702 -1
$a Veronesi $b Umberto $3 sllk_un_auth*p0008563 $4 340 801 -0
$a SK $b BA006 $c 19981223 $g AACR2 SYS c013953 LBL ^^^^^nam^^22^^^^^^^^450^ 005 20060908125143.0 010 $a 0-19-262664-7 100 $a 19951201d1995 m y0sloc0103 ba 101 0-
$a eng 102 $a GB 105 $a a z 000yy 200 1-
$a Oxford textbook of oncology $h Vol. 2 $f edit. Michael Peckham, Herbert M. Pinedo, Umberto Veronesi 210 $a Oxford, U.K. $c Oxford University Press $d 1995 215 $a xxiii, s. 1243-2481, 124 $c il. 541 0-
$a Oxfordská učebnica onkológie. Zv. 2 606 $a onkológia lekárska $2 mesh $3 sllk_un_auth*d008495 606 $a nádory prsníka $2 mesh $3 sllk_un_auth*d001943 606 $a nádory ženských pohlavných orgánov $2 mesh $3 sllk_un_auth*d005833 606 $a nádory urologické $2 mesh $3 sllk_un_auth*d014571 606 $a nádory hrudníka $2 mesh $3 sllk_un_auth*d013899 606 $a nádory pľúc $2 mesh $3 sllk_un_auth*d008175 606 $a leukémia $2 mesh $3 sllk_un_auth*d007938 606 $a Hodgkinova choroba $2 mesh $3 sllk_un_auth*d006689 606 $a lymfóm non-Hodgkinov $2 mesh $3 sllk_un_auth*d008228 606 $3 sllk_un_auth*d012983 $a nádory mäkkých tkanív $2 mesh 606 $a Ewingov sarkóm $2 mesh $3 sllk_un_auth*d012512 606 $a osteosarkóm $2 mesh $3 sllk_un_auth*d012516 606 $a nádory $x dieťa $2 mesh $3 sllk_un_auth*d009369 606 $a nádory centrálneho nervového systému $2 mesh $3 sllk_un_auth*d016543 606 $a nádory endokrinných žliaz $2 mesh $3 sllk_un_auth*d004701 606 $a staging nádorov $2 mesh $3 sllk_un_auth*d009367 606 $a nádory $x ľudia vyššieho veku $2 mesh $3 sllk_un_auth*d009369 606 $a ošetrovateľstvo onkologické $2 mesh $3 sllk_un_auth*d009859 675 $a 616-006.6-073.432.19-085 $v 1. stred. $z slo 702 -1
$a Peckham $b Michael J. $3 sllk_un_auth*p0003400 $4 340 702 -1
$a Pinedo $b H. M. $g Herbert M. $3 sllk_un_auth*p0002717 $4 340 702 -1
$a Veronesi $b Umberto $3 sllk_un_auth*p0008563 $4 340 801 -0
$a SK $b BA006 $c 19981223 $g AACR2 SYS c054349 LBL ^^^^^nam^^22^^^^^^^^450^ 005 20000609135734.0 100 $a 20000419d1985 m y0sloc0103 ba 101 0-
$a eng 102 $a NL 105 $a y z 000yy 200 1-
$a <The> cancer pharmacology annual $h 3 $f B. A. Chabner (ed.), H. M. Pinedo (ed.) 210 $a Amsterdam $c Elsevier $d 1985 215 $a xi, 216 s. 606 $a nádory $2 mesh $3 sllk_un_auth*d009369 606 $a farmakoterapia $x ročenky $2 mesh $3 sllk_un_auth*d004358 675 $a 616-006.6:615.277.3 $v 1. stred. $z slo 702 -1
$3 sllk_un_auth*p0002718 $a Chabner $b B. A. $g Bruce A. $4 340 702 -1
$3 sllk_un_auth*p0002717 $a Pinedo $b H. M. $g Herbert M. $4 340 801 -0
$a SK $b BA006 $c 20000419 $g AACR2